Cytokinetics gets its US approval Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 22 December, 2025

Biopharma’s year doesn’t start on January 1. It starts in San Francisco. Join Endpoints for bold conversations with the leaders shaping what's next. Plus, get access to the Endpoints Hub — our premium coworking and meeting space just steps from the action. Reserve your spot now.

spotlight White House unveils nine more ‘most favored nation’ deals as Trump says he'll target health insurers next

news AstraZeneca bets up to $2B on Jacobio’s pan-KRAS inhibitor for cancer Aktis Oncology files for IPO to fund Lilly-partnered radiopharma pipeline FDA approves Cytokinetics’ heart drug, giving it an edge over BMS rival

Client Engagement Mgr - Life Sciences Strategy & Intelligence Sedulo Group Remote Analyst – Life Sciences Strategy & Intelligence Sedulo Group Remote Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Jan 28 11:00am ET How breakthrough RWE is powering a new era of blood cancer research sponsored by Flatiron Jan 22 12:00pm ET Scaling for a New Era: The Rise of Radiopharma sponsored by PharmaLogic

Share your perspective. Endpoints is fielding the next Biopharma Sentiment Index (BPSI), a three-minute survey that distills thousands of industry views into a quarterly benchmark. It’s one of the clearest snapshots of how people inside biopharma see the year ahead. Add your voice today.

endpoints pharma Senators point fingers over who blocked the rare disease voucher reauthorization BioMarin to buy Amicus for $4.8B, gaining pair of rare disease medicines Galapagos looks for ways to put €3B to use, as last asset standing posts mixed results

in case you missed it 1. Joe Jimenez's Aditum goes to Fosun for major biobuck-loaded collaboration 2. China's biotech sector is advancing faster than thought, US commission says 3. Peer Review Novo obesity partner nabs Pfizer vet as CBO; CureVac's leadership clears out as BioNTech takes over 4. News Briefing Altimmune advances in MASH; New China obesity biotech; Ipsen Phase 2 fail 5. UK committee demands ‘much-needed clarity’ on UK-US pharma trade deal 6. Catalent handed two Form 483s, including for Sarepta gene therapy site 7.